Chemed Corp

Latest Results (16.11.2025):

Chemed Corp reported its third-quarter 2025 financial results, showing moderate revenue growth amid declining earnings. The consolidated operating revenue increased 3.1% to $624.9 million; however, GAAP Diluted EPS fell by 10.8% to $4.46 and Adjusted Diluted EPS declined 6.6% to $5.27. While the VITAS segment experienced improvements in patient revenue and admissions, both the broader operations and select segment metrics reflected downward pressure on net income and adjusted EBITDA margins. Additionally, the company repurchased 407,500 shares during the quarter.

Revenue & EPS Trends

Chemed Corp’s overall revenue grew by 3.1% in Q3 2025 to reach $624.9 million. Despite this growth, the company’s GAAP Diluted EPS declined by 10.8% to $4.46, and Adjusted Diluted EPS dropped 6.6% to $5.27, highlighting challenges in translating revenue gains into earnings.

VITAS Segment Performance

In the VITAS segment, key operational metrics showed healthy increases: net patient revenue climbed 4.2% to $407.7 million, the average daily census rose by 2.5% to 22,327, and admissions increased 5.6% to 17,714. However, the segment also saw a 9.0% drop in net income (excluding discrete items) and a 3.8% decline in adjusted EBITDA, with the adjusted EBITDA margin shrinking by 157 basis points.

Additional Operational Highlights

The report noted that in other parts of the business, such as Roto-Rooter, there was a decrease in gross margins—from 52.9% in the prior year quarter to 50.7% in Q3 2025. Furthermore, as part of its capital management efforts, Chemed repurchased 407,500 shares during the quarter while reiterating its guidance for the full year 2025.